Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1362-1372

  Dmitrieva, Nina ^a   Yu, Lianbo ^a   Viapiano, Mariano ^a,b   Cripe, Timothy P ^c   Chiocca, E Antonio ^a   Glorioso, Joseph C ^d   Kaur, Balveen ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN ABC LYASE; ONCOLYTIC HERPES VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS LOAD; VIRUS RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHONDROITIN ABC LYASE; CHONDROITIN SULFATES; GENE DELETION; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIRUSES; PROTEOGLYCANS;

EID: 79952719169     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2213     Document Type: Article

References (47)

1. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76. (Pubitemid 41766784)
2. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an over-view. Curr Opin Mol Ther 2009;11:43-53.
3. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009;17:199-207.
4. Kaur B, Cripe TP, Chiocca EA. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009;9:341-55.
5. Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 2009;6:558-69.
6. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503. (Pubitemid 30262444)
7. Zamecnik J. The extracellular space and matrix of gliomas. Acta Neuropathol (Berl) 2005;110:435-42. (Pubitemid 41672336)
8. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007;67:4399-407. (Pubitemid 46815089)
9. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010;18:1275-83.
10. Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 2000;11: 2219-30.
11. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 2010;17: 1200-5.
12. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006;66:2509-13.
13. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006;98:1482-93. (Pubitemid 44605593)
14. Wang Y, Luo W, Reiser G. Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions. Cell Mol Life Sci 2008;65:237-52. (Pubitemid 351161480)
15. Rosenberg GA, Estrada E, Kelley RO, Kornfeld M. Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat. Neurosci Lett 1993;160:117-9. (Pubitemid 23287616)
16. Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 2007; 16:1098-112. (Pubitemid 47062730)
17. Viapiano MS, Matthews RT. From barriers to bridges: chondroitin sulfate proteoglycans in neuropathology. Trends Mol Med 2006; 12:488-96. (Pubitemid 44441998)
18. Viapiano MS, Lawler SE. Glioma invasion: mechanisms and therapeutic challenges. In: Van MeirEG, editor. CNS Cancer Models, Prognostic factors and targets. Totowa, NJ: Humana Press; 2009;1219-52.
19. Rhodes KE, Fawcett JW. Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? J Anat 2004;204:33-48.
20. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Water-man P, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18:285-94.
21. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001;61:5336-9. (Pubitemid 32694905)
22. Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol 2008;10:690-9.
23. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005;65:2832-9. (Pubitemid 40490086)
24. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006;13:705-14.
25. Prabhakar V, Capila I, Bosques CJ, Pojasek K, Sasisekharan R. Chondroitinase ABC I from Proteus vulgaris: cloning, recombinant expression and active site identification. Biochem J 2005;386:103-12. (Pubitemid 40289229)
26. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005;24:3632-42. (Pubitemid 40756232)
27. Jones LL, Margolis RU, Tuszynski MH. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp Neurol 2003;182:399-411. (Pubitemid 36937092)
28. Bandtlow CE, Zimmermann DR. Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev 2000;80:1267-90.
29. Vargova L, Homola A, Zamecnik J, Tichy M, Benes V, Sykova E. Diffusion parameters of the extracellular space in human gliomas. Glia 2003;42:77-88. (Pubitemid 36427423)
30. Garcia-Alias G, Barkhuysen S, Buckle M, Fawcett JW. Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. Nat Neurosci 2009;12:1145-51.
31. Rolls A, Cahalon L, Bakalash S, Avidan H, Lider O, Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J 2006;20:547-9. (Pubitemid 46671245)
32. Crespo D, Asher RA, Lin R, Rhodes KE, Fawcett JW. How does chondroitinase promote functional recovery in the damaged CNS?Exp Neurol 2007;206:159-71.
33. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004;18:754-6.
34. Hu B, Kong LL, Matthews RT, Viapiano MS. The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem 2008;283:24848-59.
35. Moon LD, Asher RA, Fawcett JW. Limited growth of severed CNS axons after treatment of adult rat brain with hyaluronidase. J Neurosci Res 2003;71:23-37. (Pubitemid 36008399)
36. Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007; 96:1560-8. (Pubitemid 46762960)
37. Viapiano MS, Hockfield S, Matthews RT. BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 2008;88:261-72.
38. Gladson CL. The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 1999;58:1029-40. (Pubitemid 29468264)
39. Grumet M, Friedlander DR, Sakurai T. Functions of brain chondroitin sulfate proteoglycans during developments: interactions with adhesion molecules. Perspect Dev Neurobiol 1996;3:319-30. (Pubitemid 126839139)
40. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007;67:10664-8. (Pubitemid 350145891)
41. Lin R, Kwok JC, Crespo D, Fawcett JW. Chondroitinase ABC has a long-lasting effect on chondroitin sulphate glycosaminoglycan content in the injured rat brain. J Neurochem 2008;104:400-8. (Pubitemid 350293887)
42. Bruckner G, Bringmann A, Hartig W, Koppe G, Delpech B, Brauer K. Acute and long-lasting changes in extracellular-matrix chondroitin-sulphate proteoglycans induced by injection of chondroitinase ABC in the adult rat brain. Exp Brain Res 1998;121:300-10. (Pubitemid 28371962)
43. Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006;7:628-43. (Pubitemid 44106745)
44. Banfield BW, Leduc Y, Esford L, Visalli RJ, Brandt CR, Tufaro F. Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology 1995;208:531-9.
45. Le Doux JM, Morgan JR, Snow RG, Yarmush ML. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1996;70:6468-73. (Pubitemid 26266876)
46. Le Doux JM, Morgan JR, Yarmush ML. Removal of proteoglycans increases efficiency of retroviral gene transfer. Biotechnol Bioeng 1998;58:23-34. (Pubitemid 28103338)
47. Le Doux JM, Morgan JR, Yarmush ML. Differential inhibition of retro-virus transduction by proteoglycans and free glycosaminoglycans. Biotechnol Prog 1999;15:397-406. (Pubitemid 29270684)